Exploration of novel ligands to target C-C Motif Chemokine Receptor 2 (CCR2) as a promising pharmacological treatment against traumatic brain injury
Open Access
- 20 May 2022
- journal article
- research article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 151, 113155
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- Role of chemokine CCL2 and its receptor CCR2 in neurodegenerative diseasesArchives of Pharmacal Research, 2013
- Measuring and comparing structural fluctuation patterns in large protein datasetsBioinformatics, 2012
- Ion−π Interactions in Ligand Design for Anions and Main Group CationsAccounts of Chemical Research, 2012
- Structural Insights from Binding Poses of CCR2 and CCR5 with Clinically Important Antagonists: A Combined In Silico StudyPLOS ONE, 2012
- Role of Chemokines in CNS Health and Pathology: A Focus on the CCL2/CCR2 and CXCL8/CXCR2 NetworksJournal of Cerebral Blood Flow & Metabolism, 2009
- Moving targets: cell migration inhibitors as new anti-inflammatory therapiesNature Immunology, 2008
- Radius of gyration as an indicator of protein structure compactnessMolecular Biology, 2008
- Models of S/π interactions in protein structures: Comparison of the H2S–benzene complex with PDB dataProtein Science, 2007
- Site-directed mutagenesis of CCR2 identified amino acid residues in transmembrane helices 1, 2, and 7 important for MCP-1 binding and biological functionsBiochemical and Biophysical Research Communications, 2005
- Molecular Properties That Influence the Oral Bioavailability of Drug CandidatesJournal of Medicinal Chemistry, 2002